UBS Group AG - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$0260.0%0.00%
Q2 2022$0
-100.0%
26
-99.4%
0.00%
Q1 2022$6,000
-50.0%
4,000
+78.7%
0.00%
Q4 2021$12,000
-20.0%
2,238
-17.4%
0.00%
Q3 2021$15,0002,708
+4489.8%
0.00%
Q2 2021$059
+126.9%
0.00%
Q1 2021$0
-100.0%
26
-99.4%
0.00%
Q4 2020$22,0004,5840.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 381,713$1,828,0001.56%
Cowen Prime Services LLC 441,918$2,117,0000.94%
Nantahala Capital Management 363,622$1,742,0000.05%
GSA CAPITAL PARTNERS LLP 45,221$217,0000.04%
HighMark Wealth Management LLC 6,666$32,0000.03%
Tower Research Capital LLC (TRC) 10,572$51,0000.00%
Qube Research & Technologies Ltd 12,034$58,0000.00%
Squarepoint Ops LLC 25,597$123,0000.00%
Ironwood Financial, llc 103$00.00%
OSAIC HOLDINGS, INC. 24$00.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders